Tesamorelin vs CJC-1295 DAC

Verdict: Same receptor, different philosophies. Tesamorelin: daily injections, real human trials, the only GHRH analog with regulatory approval and hard visceral-fat data — at a premium price. CJC-1295 DAC: one or two injections a week thanks to its albumin-binding Drug Affinity Complex, community-priced, but its continuous 'GH bleed' flattens the natural pulse pattern that purists try to preserve. Evidence and pulse fidelity: tesamorelin. Convenience and cost: DAC.

Side by side

TesamorelinCJC-1295 DAC
Typical dose1 mg–2 mg1 mg–2 mg
Frequencydaily1–2x weekly
Administrationsubcutaneous injectionsubcutaneous injection
Common vials5 mg, 10 mg2 mg, 5 mg
Typical mix5 mg + 2 ml water2 mg + 2 ml water
Units for typical dose80 units (2 mg)200 units (2 mg)

The pulse question

Natural GH release is pulsatile, and secretagogue lore holds that preserving pulses matters for downstream effects and safety. Tesamorelin, injected daily, amplifies pulses while roughly following the natural rhythm. CJC-1295 DAC's week-long half-life elevates GHRH tone continuously — effective at raising IGF-1, but it's the least pulse-faithful option in the category.

Evidence asymmetry

Tesamorelin carries multiple RCTs and an FDA approval (visceral adipose reduction in HIV lipodystrophy) — you can read effect sizes instead of forum anecdotes. CJC-1295 DAC has early pharmacokinetic studies showing sustained GH/IGF-1 elevation, then a clinical program that stopped; everything since is community protocol.

Cost and logistics

Typical patterns: tesamorelin 1–2 mg daily (30–60 injections/month); CJC-1295 DAC 2 mg once or twice weekly (4–8/month). DAC wins dramatically on both syringe count and monthly cost, which is why it stays popular despite the pulse debate.

Can you stack them?

Pick ONE GHRH analog — combining them stacks the same signal. Either pairs with ipamorelin; with DAC the secretagogue also partially restores a pulse shape on top of the elevated baseline.

More comparisons

Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.